These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9839299)

  • 1. Determinants of Gd-enhanced MRI response to IFN-beta-1a treatment in relapsing-remitting multiple sclerosis.
    Koudriavtseva T; Pozzilli C; Fiorelli M; Gasperini C; Bagnato F; Galgani S; Frontoni M; Ciccarelli O; Bastianello S
    Mult Scler; 1998 Oct; 4(5):403-7. PubMed ID: 9839299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis].
    Waubant E; Sloan R; Andersson PB; Goodkin D
    Rev Neurol (Paris); 1999; 155 Suppl 2():S20-3. PubMed ID: 10367321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.
    Pozzilli C; Bastianello S; Koudriavtseva T; Gasperini C; Bozzao A; Millefiorini E; Galgani S; Buttinelli C; Perciaccante G; Piazza G; Bozzao L; Fieschi C
    J Neurol Neurosurg Psychiatry; 1996 Sep; 61(3):251-8. PubMed ID: 8795595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.
    Lus G; Romano F; Scuotto A; Accardo C; Cotrufo R
    Eur Neurol; 2004; 51(1):15-20. PubMed ID: 14631124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.
    Paolillo A; Pozzilli C; Giugni E; Tomassini V; Gasperini C; Fiorelli M; Mainero C; Horsfield M; Galgani S; Bastianello S; Buttinelli C
    Eur J Neurol; 2002 Nov; 9(6):645-55. PubMed ID: 12453081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
    Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
    Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
    Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum soluble intercellular adhesion molecule-I in MS: relation to clinical and Gd-MRI activity and to rIFN beta-Ib treatment.
    Trojano M; Avolio C; Ruggieri M; Defazio G; Giuliani F; Paolicelli D; Livrea P
    Mult Scler; 1998 Jun; 4(3):183-7. PubMed ID: 9762671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining interferon beta response status in multiple sclerosis patients.
    Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E
    Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis.
    Richert ND; Ostuni JL; Bash CN; Leist TP; McFarland HF; Frank JA
    Mult Scler; 2001 Feb; 7(1):49-58. PubMed ID: 11321194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images.
    Gasperini C; Pozzilli C; Bastianello S; Giugni E; Horsfield MA; Koudriavtseva T; Galgani S; Paolillo A; Haggiag S; Millefiorini E; Fieschi C
    J Neurol Neurosurg Psychiatry; 1999 Nov; 67(5):579-84. PubMed ID: 10519861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients.
    Rovaris M; Capra R; Martinelli V; Gasperini C; Prandini F; Pozzilli C; Comi G; Filippi M
    J Neurol Sci; 1999 Dec; 171(2):130-4. PubMed ID: 10581379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of interferon beta in relapsing-remitting multiple sclerosis.
    Etheridge LJ; Beverley DW; Ferrie C; McManus E
    Arch Dis Child; 2004 Aug; 89(8):789-91. PubMed ID: 15269086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.